医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Taro to Announce Second Quarter Results on November 9, 2014

2014年11月06日 AM05:26
このエントリーをはてなブックマークに追加


 

HAWTHORNE, N.Y.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2014, on Sunday, November 9, 2014.

The Company will conduct an earnings call at 8:30 am EST on Monday, November 10, 2014, where senior management will discuss the Company’s performance and answer questions from participants.

The release will be accessible on Taro’s website at www.taro.com.

Earnings call (8:30 am EST, Monday, November 10, 2014)

To participate in this conference call, please dial the numbers provided below five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, www.taro.com. A transcript of this earnings call will also be available on the website.

Summary of events

Event       Date and time       Telephone number/ website
Earnings release       November 9, 2014      

www.taro.com

Earnings conference call       8:30 am EST

November 10, 2014

     

Participant Toll-Free Dial-In Number: +1 (844) 421-0601

Participant International Dial-In Number: +1 (716) 247-5800

ID: 25505207

 

Via audio webcast, details of which will be made available on www.taro.com

Replay of conference call       November 10, 2014 to

November 24, 2014

     

+1 (855) 859-2056 or +1 (404) 537-3406

ID: 25505207

 

Via audio webcast playback, details of which will be made available on www.taro.com

           

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

CONTACT

Taro Pharmaceutical Industries Ltd.
Michael Kalb, +1
914-345-9001
GVP, CFO
Michael.Kalb@taro.com
or
William
J. Coote,
+1 914-345-9001
William.Coote@taro.com

同じカテゴリーの記事 

  • 大手CDMOのPCIファーマ・サービシズが初の包括ESG報告書を発表
  • Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
  • 领先的合同开发和制造组织PCI Pharma Services发布首份综合ESG报告
  • EverEx Secures iF Design Award for “MORA,” a Leading Musculoskeletal Rehabilitation Solution
  • Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer